Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
Ann Intern Med. 2011 Oct 4;155(7):434-47. doi: 10.7326/0003-4819-155-7-201110040-00006.
Overweight and obesity in adults are common and adversely affect health.
To summarize effectiveness and harms of primary care-relevant weight-loss interventions for overweight and obese adults.
MEDLINE, Cochrane Central Register of Controlled Trials, and PsycINFO from January 2005 to September 2010; systematic reviews for identifying trials before 2005.
Two investigators appraised 6498 abstracts and 648 articles. Clinical trials were included if control groups received minimal interventions. Articles were rated as good, fair, or poor by using design-specific criteria.
One investigator abstracted study characteristics and findings for good- and fair-quality studies; a second checked them.
Behaviorally based treatment resulted in 3-kg (6.6-lb) greater weight loss in intervention than control participants after 12 to 18 months, with more treatment sessions associated with greater loss. Limited data suggest weight-loss maintenance for 1 year or more. Orlistat plus behavioral intervention resulted in 3-kg (6.6-lb) more weight loss than did placebo after 12 months. Metformin resulted in less weight loss. Data on effects of weight-loss treatment on long-term health outcomes (for example, death and cardiovascular disease) were insufficient. Weight-loss treatment reduced diabetes incidence in participants with prediabetes. Effects on intermediate outcomes (for example, lipids and blood pressure) were mixed and small. Data on serious medication harms were insufficient. Medications commonly caused withdrawals due to gastrointestinal symptoms.
Few studies reported health outcomes. Behaviorally based treatments were heterogeneous and specific elements were not well-described. Many studies could not be pooled because of insufficient reporting of variance data. Medication trials had high attrition, lacked postdiscontinuation data, and were inadequately powered for rare adverse effects.
Behaviorally based treatments are safe and effective for weight loss and maintenance.
Agency for Healthcare Research and Quality.
成年人超重和肥胖很常见,而且会对健康造成不良影响。
总结对超重和肥胖成年人进行初级保健相关减肥干预的效果和危害。
2005 年 1 月至 2010 年 9 月期间的 MEDLINE、Cochrane 对照试验中心注册库和 PsycINFO;用于确定 2005 年之前试验的系统评价。
两名调查人员评估了 6498 份摘要和 648 篇文章。如果对照组接受最低限度的干预,则将临床试验纳入。使用特定设计标准对文章进行了良好、中等和差的评级。
一名调查员提取了良好和中等质量研究的研究特征和结果;第二名调查员对其进行了检查。
在 12 至 18 个月后,行为治疗组的干预组参与者体重减轻 3 公斤(6.6 磅),治疗次数越多,体重减轻越多。有限的数据表明,体重维持 1 年或更长时间。奥利司他加行为干预治疗 12 个月后比安慰剂组多减重 3 公斤(6.6 磅)。二甲双胍导致体重减轻较少。关于减肥治疗对长期健康结果(如死亡和心血管疾病)影响的数据不足。减肥治疗可降低有前驱糖尿病患者的糖尿病发病率。对中间结果(如血脂和血压)的影响混杂且较小。关于严重药物危害的数据不足。药物通常因胃肠道症状而停药。
很少有研究报告健康结果。行为治疗组差异较大,具体内容描述不充分。由于方差数据报告不足,许多研究无法进行汇总。药物试验失访率高,缺乏停药后数据,且罕见不良反应的研究力度不足。
行为治疗对减肥和维持体重是安全有效的。
美国医疗保健研究与质量局。